ATE417937T1 - Materialien und verfahren in verbindung mit brustkrebsdiagnose - Google Patents

Materialien und verfahren in verbindung mit brustkrebsdiagnose

Info

Publication number
ATE417937T1
ATE417937T1 AT04768731T AT04768731T ATE417937T1 AT E417937 T1 ATE417937 T1 AT E417937T1 AT 04768731 T AT04768731 T AT 04768731T AT 04768731 T AT04768731 T AT 04768731T AT E417937 T1 ATE417937 T1 AT E417937T1
Authority
AT
Austria
Prior art keywords
tumours
breast
breast cancer
materials
confidence
Prior art date
Application number
AT04768731T
Other languages
German (de)
English (en)
Inventor
Kun Yu
Patrick Tan
Original Assignee
Ncc Technology Ventures Pte Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ncc Technology Ventures Pte Lt filed Critical Ncc Technology Ventures Pte Lt
Application granted granted Critical
Publication of ATE417937T1 publication Critical patent/ATE417937T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04768731T 2003-10-03 2004-10-01 Materialien und verfahren in verbindung mit brustkrebsdiagnose ATE417937T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0323226.1A GB0323226D0 (en) 2003-10-03 2003-10-03 Materials and methods relating to breast cancer diagnosis

Publications (1)

Publication Number Publication Date
ATE417937T1 true ATE417937T1 (de) 2009-01-15

Family

ID=29415485

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768731T ATE417937T1 (de) 2003-10-03 2004-10-01 Materialien und verfahren in verbindung mit brustkrebsdiagnose

Country Status (9)

Country Link
US (1) US20080052007A1 (fr)
EP (1) EP1668151B1 (fr)
JP (1) JP2007508008A (fr)
CN (1) CN1910292A (fr)
AT (1) ATE417937T1 (fr)
DE (1) DE602004018521D1 (fr)
GB (1) GB0323226D0 (fr)
TW (1) TW200526789A (fr)
WO (1) WO2005033336A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435529B2 (ja) * 2005-09-02 2014-03-05 東レ株式会社 腎ガン診断、腎ガン患者予後予測のための組成物および方法
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes
WO2008049953A1 (fr) 2006-10-23 2008-05-02 Neocodex, S.L. Méthode de pronostic et/ou de diagnostic in vitro de l'hypersensibilité aux oestrogènes ou à des substances ayant une activité oestrogénique
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
TWI470082B (zh) * 2010-05-04 2015-01-21 Univ Nat Taiwan 檢測犬癌症之方法
CN103403187A (zh) * 2011-01-18 2013-11-20 艾沃锐斯特基因有限公司 结肠直肠癌复发的预后特征
US20150261859A1 (en) * 2014-03-11 2015-09-17 International Business Machines Corporation Answer Confidence Output Mechanism for Question and Answer Systems
WO2017053535A1 (fr) * 2015-09-25 2017-03-30 University Of New England Procédés et diagnostics pour la détection du cancer et le suivi du traitement
US11071517B2 (en) * 2015-11-10 2021-07-27 The Trustees Of The University Of Pennsylvania Machine implemented methods, systems, and apparatuses for improving diagnostic performance
KR102596028B1 (ko) 2017-06-13 2023-10-31 콘메드 코포레이션 후퇴 가능한 블레이드 또는 훅을 갖는 연조직 절단 기구
US11009507B2 (en) 2018-09-14 2021-05-18 University Of New England Methods and diagnostics for cancer detection and treatment monitoring
KR20240158376A (ko) 2018-10-03 2024-11-04 콘메드 코포레이션 스스로 잠김, 다중-위치, 및 슬라이드 버튼에 의해 선형으로 작동되는 집어넣을 수 있는 블래이드 또는 후크를 갖는 부드러운 조직 절단 도구
CN119265239B (zh) * 2024-12-11 2025-07-22 宁波大学 一种非治疗目的的glyr1蛋白质在调控肾透明细胞癌细胞增殖和/或迁移中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002307466A1 (en) * 2001-04-20 2002-11-05 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
EP1410011B1 (fr) * 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnostic et prevision du cancer du sein chez des patients
AU2003205913A1 (en) * 2002-02-20 2003-09-09 Ncc Technology Ventures Pte Limited Materials and methods relating to cancer diagnosis

Also Published As

Publication number Publication date
US20080052007A1 (en) 2008-02-28
DE602004018521D1 (de) 2009-01-29
CN1910292A (zh) 2007-02-07
WO2005033336A3 (fr) 2005-09-29
EP1668151B1 (fr) 2008-12-17
TW200526789A (en) 2005-08-16
EP1668151A2 (fr) 2006-06-14
JP2007508008A (ja) 2007-04-05
WO2005033336A2 (fr) 2005-04-14
GB0323226D0 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
ATE417937T1 (de) Materialien und verfahren in verbindung mit brustkrebsdiagnose
EP4427810A3 (fr) Procédés de traitement utilisant une thérapie cellulaire adoptive
Pramanik et al. Matrix adhesion and remodeling diversifies modes of cancer invasion across spatial scales
EA202191958A1 (ru) Способы и соединения
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
Wang et al. Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer
WO2020231997A9 (fr) Arn non codant pour le traitement du cancer de la vessie
Woelber et al. EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome
WO2021007525A3 (fr) Méthodes et agents pour le dépistage et le traitement du cancer
Zou et al. Positive TIGIT and VISTA Expression Predict Worse Prognosis in Cervical Cancer Patients Treated with (Chemo) Radiotherapy
Moazeni-Roodi et al. An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer
Stanland et al. Molecular features and translational outlook for Epstein–Barr virus-associated gastric cancer
CN1317389C (zh) 抑制纤连蛋白表达的反义寡核苷酸的结构和用途
Schwab et al. Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Jiang et al. Subtyping diffuse large B-cell lymphoma with cell-of-origin using 32-gene expression assay in formalin-fixed paraffin-embedded tissue
Kamoun et al. Reply to Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus genomic subtypes of muscle-invasive bladder cancer: a step in the right direction but still a long way to go. Eur Urol 2020; 77: 434–5
Xie et al. STING suppresses migration of murine triple-negative breast cancer cells E0771 and 4T1 in vitro
Eusebi Classifications and prognosis of breast cancer: from morphology to molecular taxonomy
Fuhrmann et al. T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial
Muradova et al. 130 Novel method for non-invasive assessment of molecular markers of UV exposure in normal skin
Verhaegen et al. 132 Atoh1 is required for maintenance of Merkel cell carcinoma lineage identity
Gong Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study: O'Brien KM, Cole SR, Tse CK, et al (Univ of North Carolina, Chapel Hill; et al) Clin Cancer Res 16: 6100-6110, 2010
ANNA et al. Somatostatin and Analogs: Biological and Molecular Insights from In Vitro Breast Cancer.
Bunt et al. ETMR-09. In vitro modelling of embryonal tumors with multilayered rosettes (ETMR) and other novel brain tumor types

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties